Information Provided By:
Fly News Breaks for February 21, 2017
JNCE
Feb 21, 2017 | 05:53 EDT
JPMorgan analyst Cory Kasimov started Jounce Therapeutics with an Overweight rating and $28 price target. The analyst believes current share levels offer an attractive entry for the pure play immuno-oncology company.
News For JNCE From the Last 2 Days
There are no results for your query JNCE